MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Total Assets 2011-2026 | DRRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.2 M | 60.1 M | 92 M | 75.6 M | 86 M | 50 M | 53.1 M | 40.5 M | 46.8 M | 50.1 M | 40.8 M | 45.9 M | 49.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 92 M | 40.5 M | 56.6 M |
Quarterly Total Assets DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 M | 14.4 M | 24.1 M | 29.9 M | 36.2 M | 54.7 M | 48.7 M | 58.3 M | 60.1 M | 68.5 M | - | 80.5 M | 92 M | 98 M | 106 M | 116 M | 75.6 M | 75.6 M | 75.6 M | 75.6 M | 86 M | 86 M | 86 M | 86 M | 50 M | 50 M | 50 M | 50 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 46.8 M | 46.8 M | 46.8 M | 46.8 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 49.2 M | 49.2 M | 49.2 M | 49.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 M | 12.5 M | 55.5 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 9.69 | 0.52 % | $ 1.34 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.42 | 3.01 % | $ 86.3 M |  Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 1.04 | 0.97 % | $ 24.3 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.93 B | $ 2.62 | 1.55 % | $ 1.39 B | Canada |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.21 | 2.43 % | $ 420 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.36 | -0.73 % | $ 3.37 M | Canada |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.28 | -2.56 % | $ 2.83 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.35 | 7.03 % | $ 47.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.08 | 1.8 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.29 | - | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 23.49 | 1.25 % | $ 1.09 B | USA |
 |
Evolus
EOLS
|
226 M | $ 4.37 | -1.35 % | $ 282 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 6.94 | 4.2 % | $ 4.29 B | Canada |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.88 | -2.13 % | $ 43.9 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.5 | 1.05 % | $ 16.2 B | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.6 | 2.41 % | $ 10.5 M |  China |
 |
cbdMD
YCBD
|
10.6 M | $ 0.81 | 4.7 % | $ 3.49 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 18.57 | 12.48 % | $ 119 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.44 | 1.24 % | $ 321 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 0.97 | 1.5 % | $ 104 M | Canada |
 |
Harrow Health
HROW
|
399 M | $ 36.35 | 3.27 % | $ 1.34 B | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.29 | - | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |